CD81-FC recombinant protein
- Catalog No.：YD3079
- Reactivity：Human;
- Purity：
- >90% as determined by SDS-PAGE
- Protein Name：
- CD81 antigen (26 kDa cell surface protein TAPA-1) (Target of the antiproliferative antibody 1) (Tetraspanin-28) (Tspan-28) (CD antigen CD81)
- Sequence：
- Amino acid:34-63,with FC tag.
- Formulation：
- Phosphate-buffered solution
- Storage Stability：
- -15°C to -25°C/1 year(Avoid freeze / thaw cycles)
- Other Name：
- CD81 antigen ;26 kDa cell surface protein TAPA-1;Target of the antiproliferative antibody 1;Tetraspanin-28;Tspan-28;CD antigen CD81;CD81;TAPA1;TSPAN28;
- Function：
- Structural component of specialized membrane microdomains known as tetraspanin-enriched microdomains (TERMs), which act as platforms for receptor clustering and signaling. Essential for trafficking and compartmentalization of CD19 receptor on the surface of activated B cells (PubMed:16449649, PubMed:20237408, PubMed:27881302). Upon initial encounter with microbial pathogens, enables the assembly of CD19-CR2/CD21 and B cell receptor (BCR) complexes at signaling TERMs, lowering the threshold dose of antigen required to trigger B cell clonal expansion and antibody production (PubMed:15161911, PubMed:20237408). In T cells, facilitates the localization of CD247/CD3 zeta at antigen-induced synapses with B cells, providing for costimulation and polarization toward T helper type 2 phenotype (PubMed:22307619, PubMed:23858057, PubMed:8766544). Present in MHC class II compartments, may also play a
- Subcellular Location：
- Cell membrane ; Multi-pass membrane protein . Basolateral cell membrane ; Multi-pass membrane protein . Note=Associates with CLDN1 and the CLDN1-CD81 complex localizes to the basolateral cell membrane. .
- Expression：
- Expressed on B cells (at protein level) (PubMed:20237408). Expressed in hepatocytes (at protein level) (PubMed:12483205). Expressed in monocytes/macrophages (at protein level) (PubMed:12796480). Expressed on both naive and memory CD4-positive T cells (at protein level) (PubMed:22307619).
